Poly (ADP ribose) polymerase (PARP) inhibitors have shown substantial efficacy in BRCA-mutated ovarian cancer for several years, and their indication has gradually been extended to other tumour locations such as breast, prostate and pancreas.
[European Journal of Cancer]
6445212
AAAAAAAA
items
1
apa
0
default
asc
1
173247
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/